Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Metabolic syndrome; obesity

MicroRNA-378 (miR-378); miR-378*

Mouse studies suggest inhibiting miR-378 could help prevent obesity and metabolic syndrome. In mice, deletion of miR-378 and miR-378*, which both originate from the same miRNA precursor, increased resistance to diet-induced obesity compared with normal expression of the miRNAs. In miR-378 and miR-378* knockout mice, energy expenditure and mitochondria oxidative capacity were greater than those in wild-type controls. Next steps could include developing compounds to inhibit miR-378 signaling.
miRagen Therapeutics Inc. has a preclinical program to validate miR-378 as a target for cardiometabolic diseases.

SciBX 5(38); doi:10.1038/scibx.2012.1004
Published online Sept. 27, 2012

Patent and licensing status unavailable

Carrer, M. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 4, 2012;
doi:10.1073/pnas.1207605109
Contact: Eric N. Olson, The University of Texas Southwestern Medical Center,
Dallas, Texas
e-mail:
eric.olson@utsouthwestern.edu